Application of Assisted Design of Antibody and Protein Therapeutics (ADAPT) improves efficacy of a Clostridium difficile toxin A single-domain antibody
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Application of Assisted Design of Antibody and Protein Therapeutics (ADAPT) improves efficacy of a Clostridium difficile toxin A single-domain antibody ; volume:8 ; number:1 ; day:2 ; month:2 ; year:2018 ; pages:1-11 ; date:12.2018
Scientific reports ; 8, Heft 1 (2.2.2018), 1-11, 12.2018
- Classification
-
Biowissenschaften, Biologie
- Creator
-
Sulea, Traian
- Contributor
-
Hussack, Greg
Ryan, Shannon
Tanha, Jamshid
Purisima, Enrico O.
SpringerLink (Online service)
- DOI
-
10.1038/s41598-018-20599-4
- URN
-
urn:nbn:de:101:1-2018090610463373303684
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:30 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Sulea, Traian
- Hussack, Greg
- Ryan, Shannon
- Tanha, Jamshid
- Purisima, Enrico O.
- SpringerLink (Online service)
Other Objects (12)
Antibody therapeutics
Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics
Human antibody therapeutics for viral disease
In vitro-engineered non-antibody protein therapeutics
Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression
The physiological interactome of TCR-like antibody therapeutics in human tissues
A monoclonal antibody collection for C. difficile typing ?
Applicability of predictive toxicology methods for monoclonal antibody therapeutics: status Quo and scope
Improved Antibody‐Specific Epitope Prediction Using AlphaFold and AbAdapt **
How mRNA therapeutics are entering the monoclonal antibody field
Correlation of pharmacodynamic activity, pharmacokinetics, and anti-product antibody responses to anti-IL-21R antibody therapeutics following IV administration to cynomolgus monkeys
Genetics of primary antibody deficiency
Antibody therapeutics
Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics
Human antibody therapeutics for viral disease
In vitro-engineered non-antibody protein therapeutics
Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression
The physiological interactome of TCR-like antibody therapeutics in human tissues
A monoclonal antibody collection for C. difficile typing ?
Applicability of predictive toxicology methods for monoclonal antibody therapeutics: status Quo and scope
Improved Antibody‐Specific Epitope Prediction Using AlphaFold and AbAdapt **
How mRNA therapeutics are entering the monoclonal antibody field
Correlation of pharmacodynamic activity, pharmacokinetics, and anti-product antibody responses to anti-IL-21R antibody therapeutics following IV administration to cynomolgus monkeys
Genetics of primary antibody deficiency
Antibody therapeutics
Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics
Human antibody therapeutics for viral disease
In vitro-engineered non-antibody protein therapeutics
Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression
The physiological interactome of TCR-like antibody therapeutics in human tissues
A monoclonal antibody collection for C. difficile typing ?
Applicability of predictive toxicology methods for monoclonal antibody therapeutics: status Quo and scope
Improved Antibody‐Specific Epitope Prediction Using AlphaFold and AbAdapt **
How mRNA therapeutics are entering the monoclonal antibody field
Correlation of pharmacodynamic activity, pharmacokinetics, and anti-product antibody responses to anti-IL-21R antibody therapeutics following IV administration to cynomolgus monkeys